As a post-marketing commitment, the Sponsor was required to conduct a 3-year single arm, observational study to further understand the clinical response to IVA in different subgroups of CF patients with CFTR mutations deemed responsive to IVA based on in vitro evidence [26]. The gene discussed is CFTR; the disease is cystic fibrosis.